{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:40:49Z","timestamp":1778676049009,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.4158\/ep11391.cr","type":"journal-article","created":{"date-parts":[[2012,3,27]],"date-time":"2012-03-27T21:14:03Z","timestamp":1332882843000},"page":"e114-e120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Successful Long-Term Treatment of Cushing Disease with Mifepristone (RU486)"],"prefix":"10.1016","volume":"18","author":[{"given":"Marina","family":"Basina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hau","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew R.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP11391.CR_bb0010","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing's syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11391.CR_bb0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1517\/13543784.2010.495943","article-title":"Pasireotide for the treatment of Cushing's disease","volume":"19","author":"Arnaldi","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.4158\/EP11391.CR_bb0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2174\/156802608784535011","article-title":"Glucocorticoid receptor antagonists","volume":"8","author":"Clark","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.4158\/EP11391.CR_bb0025","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00003081-199606000-00024","article-title":"Mifepristone: treatment of Cushing's syndrome","volume":"39","author":"Sartor","year":"1996","journal-title":"Clin Obstet Gynecol"},{"key":"10.4158\/EP11391.CR_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-4827(83)90282-3","article-title":"Inhibition of glucocorticosteroid action in cultured L-929 mouse fibroblasts by RU 486, a new anti-glucocorticosteroid of high affinity for the glucocorticosteroid receptor","volume":"147","author":"Jung-Testas","year":"1983","journal-title":"Exp Cell Res"},{"key":"10.4158\/EP11391.CR_bb0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.med.48.1.129","article-title":"RU486 (mifepristone): mechanisms of action and clinical uses","volume":"48","author":"Cadepond","year":"1997","journal-title":"Annu Rev Med"},{"key":"10.4158\/EP11391.CR_bb0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing's syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP11391.CR_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/jcem-73-1-187","article-title":"The endocrine effects of long-term treatment with mifepristone (RU 486)","volume":"73","author":"Lamberts","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11391.CR_bb0050","first-page":"375","article-title":"Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation","volume":"78","author":"Bertagna","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11391.CR_bb0055","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jcem-63-3-639","article-title":"Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing's syndrome","volume":"63","author":"Bertagna","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11391.CR_bb0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","article-title":"Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486","volume":"61","author":"Nieman","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11391.CR_bb0065","first-page":"3568","article-title":"Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)","volume":"86","author":"Chu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP11391.CR_bb0070","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing's syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP11391.CR_bb0075","first-page":"S18","article-title":"Glucocorticoids and glucocorticoid antagonists: lessons from RU 486","volume":"26","author":"Chrousos","year":"1988","journal-title":"Kidney Int Suppl"},{"key":"10.4158\/EP11391.CR_bb0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000314224","article-title":"Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone","volume":"92","author":"Castinetti","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP11391.CR_bb0085","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0889-8529(18)30034-3","article-title":"Apparent mineralocorticoid excess","volume":"24","author":"Funder","year":"1995","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/EP11391.CR_bb0090","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1016\/S0021-9258(18)60980-9","article-title":"Tissue-specific regulation of glucocorticoid receptor mRNA by dexamethasone","volume":"262","author":"Kalinyak","year":"1987","journal-title":"J Biol Chem"},{"key":"10.4158\/EP11391.CR_bb0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/humupd\/dmi002","article-title":"Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications","volume":"11","author":"Chabbert-Buffet","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.4158\/EP11391.CR_bb0100","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/GCO.0b013e32832e07e8","article-title":"Clinical utility of progesterone receptor modulators and their effect on the endometrium","volume":"21","author":"Spitz","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.4158\/EP11391.CR_bb0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","article-title":"The spectrum of endometrial pathology induced by progesterone receptor modulators","volume":"21","author":"Mutter","year":"2008","journal-title":"Mod Pathol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20429118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20429118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/BX887Q7J3L1047X5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:54:54Z","timestamp":1761515694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20429118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1530891X20429118"],"URL":"https:\/\/doi.org\/10.4158\/ep11391.cr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Long-Term Treatment of Cushing Disease with Mifepristone (RU486)","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP11391.CR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}